A Phase 2 interventional study of epoetin alfa and darbepoetin alfa in Neoplasms, Anemia and Cancer, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated at 76 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-19.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
This is an open-label (both the physician and the patient know which treatment is being provided), multi-center study of up to 16 weeks duration in which 450 patients will be randomly assigned (patients are assigned to a specific study group by chance) to one of three treatment groups in a 1:1:1 ratio. Patients will receive PROCRIT (epoetin alfa) 80,000 Units injected subcutaneously (under the skin) once every three weeks or 120,000 Units injected under the skin once every three weeks or ARANESP (darbepoetin alfa) 500 mcg injected under the skin once every three weeks for up to 13 weeks. PROCRIT (epoetin alfa) 80,000 Units and 120,000 Units given once every three weeks are doses and schedules that are not approved for use in the United States and are under investigation, while the ARANESP dose and schedule are approved for use in the United States. Adult patients with specific types of cancer (confirmed non-myeloid malignancy) who are scheduled to receive cyclic chemotherapy for a minimum of 12 weeks during the study and who meet all other eligibility criteria will be enrolled. This study will be conducted in approximately 80 study sites located in the United States.
The study hypothesis is that a dosing regimen of PROCRIT (Epoetin alfa) 80,000 Units or 120,000 Units given once every three weeks is non-inferior to ARANESP 500 mcg given once every three weeks with respect to the mean hemoglobin (Hb) change from baseline to Study Week 7 in anemic cancer patients receiving chemotherapy. Hemoglobin levels will be monitored throughout the study on a weekly basis and before each drug dose is administered. Drug dosing will be adjusted (ie, held, reduced, resumed at a lower dose) as needed to maintain hemoglobin values within desired ranges.
The maximum dose of PROCRIT (Epoetin alfa) allowed in this study is 120,000 Units every three weeks (Q3W) and the maximum dose of ARANESP (darbepoetin) is 500 mcg Q3W.
Safety evaluations will be conducted throughout the study and will consist of assessment of laboratory tests, vital signs, physical examinations. The occurrence and severity of adverse events, including thrombovascular events will be evaluated throughout the study.Periodic data monitoring of the study by an external Independent Data Monitoring Committee (IDMC) will be performed. The main responsibility of the IDMC is to conduct ongoing monitoring of safety and to report any irregularities back to the Sponsor along with recommendations regarding continuation of the study. Each patient will be assigned to one of three dosing schedules. All schedules will be administered by way of subcutaneous (under the skin) injection once every three weeks over a period of 13 weeks. The three dosing schedules are as follows: PROCRIT (epoetin alfa) 80,000 Units, PROCRIT (epoetin alfa) 120,000 Units or ARANESP (darbepoetin alfa) 500 mcg
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 235 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
Drug: epoetin alfa
epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
Drug: epoetin alfa
darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
Drug: darbepoetin alfa
80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
Also known as: PROCRIT
500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
Also known as: ARANESP
Hemoglobin (Hb) Change From Baseline to Study Week 7
Baseline Hb was the Hb value that was consistent with the inclusion criteria and which was obtained within 72 hours of the first dose of study medication
Time frame: Baseline (Week 1) and Week 7
Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study
Time frame: up to 16 weeks
Time to Achieve Hb >= 11 g/dL During Study
Time frame: up to 16 weeks
Number of Patients (Hb >= 11 g/dL) During Study.
Time frame: up to 16 weeks
| Milestone | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| Started | 75 | 77 | 75 |
| Completed | 31 | 37 | 42 |
| Not completed | 44 | 40 | 33 |
| Withdrew: Adverse event | 6 | 5 | 4 |
| Withdrew: Chang from original chemo stratification | 4 | 5 | 6 |
| Withdrew: Death | 3 | 0 | 1 |
| Withdrew: Disease progression | 7 | 4 | 5 |
| Withdrew: Physician decision | 13 | 10 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Completed chemotherapy | 4 | 5 | 1 |
| Withdrew: Protocol violation | 3 | 5 | 2 |
| Withdrew: Withdrawal by subject | 3 | 6 | 10 |
| participants | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study | 12 | 22 | 17 |
Baseline Hb was the Hb value that was consistent with the inclusion criteria and which was obtained within 72 hours of the first dose of study medication
| g/dL | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| Hemoglobin (Hb) Change From Baseline to Study Week 7 | 0.64 ± 1.30 | 0.40 ± 1.37 | 0.84 ± 1.28 |
| days | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| Time to Achieve Hb >= 11 g/dL During Study | 37 (29 to 50) | 44 (29 to 85) | 36 (29 to 44) |
| participants | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| Number of Patients (Hb >= 11 g/dL) During Study. | 51 | 48 | 56 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Alfa (80,000 Units) | — | 28/75 (37.3%) | 58/75 (77.3%) |
| Epoetin Alfa (120,000 Units) | — | 23/77 (29.9%) | 68/77 (88.3%) |
| Darbepoetin Alfa (500 Mcg) | — | 25/75 (33.3%) | 67/75 (89.3%) |
| Event | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| PneumoniaInfections and infestations | 4/75 | 1/77 | 2/75 |
| DehydrationMetabolism and nutrition disorders | 3/75 | 4/77 | 1/75 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/75 | 1/77 | 2/75 |
| Atrial fibrillationCardiac disorders | 3/75 | 1/77 | 0/75 |
| NeutropeniaBlood and lymphatic system disorders | 1/75 | 0/77 | 2/75 |
| Abdominal painGastrointestinal disorders | 2/75 | 1/77 | 0/75 |
| Small intestinal obstructionGastrointestinal disorders | 2/75 | 0/77 | 1/75 |
| Staphylococcal sepsisInfections and infestations | 1/75 | 0/77 | 2/75 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 0/77 | 2/75 |
| Non-small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/75 | 0/77 | 0/75 |
| Event | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 12/75 | 17/77 | 14/75 |
| FatigueGeneral disorders | 15/75 | 15/77 | 16/75 |
| DiarrhoeaGastrointestinal disorders | 13/75 | 11/77 | 10/75 |
| AnorexiaMetabolism and nutrition disorders | 12/75 | 6/77 | 5/75 |
| NauseaGastrointestinal disorders | 11/75 | 12/77 | 9/75 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/75 | 3/77 | 10/75 |
| PyrexiaGeneral disorders | 8/75 | 7/77 | 9/75 |
| VomitingGastrointestinal disorders | 7/75 | 9/77 | 8/75 |
| Oedema peripheralGeneral disorders | 8/75 | 6/77 | 6/75 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/75 | 8/77 | 7/75 |
| Age, Categorical(Participants) | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 36 | 34 | 41 | 111 |
| >=65 years | 41 | 46 | 37 | 124 |
| Age Continuous(years) | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) | Total |
|---|---|---|---|---|
| Mean | 65.05 ± 12.54 | 64.84 ± 11.66 | 63.00 ± 12.05 | 64.30 ± 12.07 |
| Sex: Female, Male(Participants) | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) | Total |
|---|---|---|---|---|
| Female | 41 | 57 | 52 | 150 |
| Male | 36 | 23 | 26 | 85 |
| Chemotherapy Type(participants) | Epoetin Alfa (80,000 Units) | Epoetin Alfa (120,000 Units) | Darbepoetin Alfa (500 Mcg) | Total |
|---|---|---|---|---|
| Platinum | 29 | 32 | 30 | 91 |
| Non-Platinum | 48 | 48 | 48 | 144 |
The record gives a start of Nov 2006, a primary completion of Mar 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →